The Fosun-backed eye disease treatment developer has filed for a $100m initial public offering, having raised over $250m in funding in the past two years.

UPMC Enterprises has co-led a seed round for the gene therapy developer.

Lumicks, which is developing single-molecule analysis technology based on research at Vrije Universiteit Amsterdam, has collected $93m.

SoftBank’s Vision Fund 2 has taken part in a series D round for Lumicks, which is developing single-molecule analysis technology.

University of Sheffield spinout Rinri Therapeutics has collected $13.9m from investors including Boehringer Ingelheim Venture Fund and UCB Ventures.

Tectonic Therapeutic is the latest venture undertaken by Harvard’s serial entrepreneur Timothy Springer, who co-led the series A round.

GV participated in a series C round that lifted the coronavirus treatment and preventative agent developer's overall funding to $466m.

Alexandria Real Estate Equities helped the cancer detection software developer through a convertible note round.

Venture Catalysts’ accelerator has now raised $70m so far and is set to reach a final close by the end of this year.

Alchemab Therapeutics has raised $80m to advance research originating at University of Oxford, Johns Hopkins University and Mount Sinai Hospital.